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The high attrition rate of cancer drug development programs is a barrier to realising the 
promise of precision oncology. We have examined if the genetic insights from genome-wide 
association studies (GWAS) of cancer can guide drug development and repurposing in 
oncology. 
  
MATERIALS AND METHODS  
Across 37 cancers we identified 955 genetic risk variants from the NHGRI-EBI GWAS Catalog. 
We linked these variants to target genes using strategies based on information on linkage-
disequilbrium, DNA 3D-structure and integration of predicted gene function and expression. 
Using the Informa Pharmaprojects database we identified genes that are targets of unique 
drugs and assessed the level of enrichment that would be afforded by incorporation of 
genetic information in pre-clinical and Phase II studies. For targets not under development 
we implemented machine learning approaches to assess druggability. 
 
RESULTS 
For all pre-clinical targets incorporation of genetic information a 2.00-fold enrichment of a 
drug being successfully approved could be achieved (95% confidence interval (CI): 1.14-3.48, 
P= 0.02). For Phase II targets a 2.75-fold enrichment was shown (95% CI: 1.42-5.35, P= 
4.2x10-3). Application of genetic information suggested potential repurposing of 15 
approved non-oncology drugs.   
 
CONCLUSION 
Our findings serve to illustrate the value of using insights from the genetics of inherited 
cancer susceptibility discovery projects as part of a data-driven strategy to inform drug 
discovery. Supporting cancer germline genetic information for prospective targets is 
available from https://cansar.icr.ac.uk/. 
 





The high attrition rate of drug development programs represents a significant barrier to fully 
realising the vision of precision oncology1. The failure of preclinical model systems to 
adequately predict efficacy in humans is leading drug developers to seek additional sources 
of evidence to inform decisions about which targets to pursue2,3. 
 
Following completion of the Human Genome Project there has been rapid progress in 
identifying inherited genetic variants influencing cancer risk through genome-wide 
association studies (GWAS) and large-scale sequencing projects4. Genome-wide association 
studies have now have been performed for most common malignancies and many rare 
tumor types, and over 900 genetic variants have been robustly demonstrated to influence 
risk4.  
 
The insights from these GWAS potentially offer an additional mechanism for selecting drug 
targets and indications, both key requirements in drug discovery. Risk single-nucleotide 
polymorphisms (SNPs) in or near a gene that may associate with the activity or expression of 
the encoded protein therefore can be used as a tool to infer the effect of pharmacological 
action on the same protein in a trial. Specifically, by extension, disease-associated SNPs 
identified by GWAS can be explicitly interpreted as a source of randomized human evidence 
to aid drug target identification and validation. 
 
Several examples serve to illustrate the application of human genetics to inform drug 
discovery by utilising knowledge of variation in genes associated with disease risk. These 
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include the targeting of 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMGCR) by 
statins for treatment of coronary heart disease5 and ustekinumab, a monoclonal inhibitor of 
interleukin-12 (IL-12) and IL-23 used to treat inflammatory bowel disease6. 
 
Here we have, using GWAS association data for 37 cancers, examined the potential for 
human genetics to guide cancer drug development and repurposing of current approved 
drugs.  
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MATERIALS AND METHODS 
 
Compiling GWAS data 
To curate cancer risk SNPs identified by GWAS we queried the National Human Genome 
Research Institute (NHGRI) GWAS catalogue7 (https://www.ebi.ac.uk/gwas/; accessed July 
2017). We imposed a number of quality control metrics, filtering by association P-value < 5 × 
10-8 and including only SNPs associated with the cancer rather than another cancer-related 
phenotype such as progression. We additionally manually added SNPs from recent cancer 
GWAS that had not yet been added to the catalog (Supplementary Table 1). We considered 
GWAS associations irrespective of their ethnicity. Gene transcript information, including 
gene annotations and transcript start sites for human build 37 were obtained from Ensembl 
biomart Genes 89 dataset (http://grch37.ensembl.org/biomart/martview/). 
 
Linking risk SNPs to target genes 
To the extent that they have been deciphered, most GWAS risk SNPs map to non-coding 
regions of the genome and influence gene regulation. Since spatial proximity between 
specific genomic regions and chromatin looping interactions are central for the regulation of 
gene expression the 3D structure of DNA means that gene proximity to the risk SNP does 
always necessarily equate to target gene. It is however, the case that regulatory effects and 
hence target genes are generally confined within topologically associated domains (TADs) of 
the genome. To link risk SNPs to target genes we therefore adopted three strategies. 
 
For linkage disequilibrium (LD) based annotation, an approach similar to that adopted by 
Finan et al., 20178 was undertaken. For each cancer risk SNP, correlated SNPs were obtained 
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for European (CEU), east Asian (CHB) and African (YRI) populations from 1000 Genomes 
Project Phase 3 using the LDlink9 web application (https://analysistools.nci.nih.gov/LDlink/). 
LD boundaries were designated by the smallest and largest genomic location of SNPs 
correlated (r2 values 0.1 to 0.9) with the reported cancer risk SNP. For SNPs where LD 
information could not be obtained, the boundaries were taken as 2.5kb on either side of the 
SNP genomic position. Gene transcription start sites were then mapped to these LD 
boundaries. 
 
Topologically associating domain boundaries encompassing each risk locus were based on 
H1 Human Embryonic Stem Cells were obtained from Schmitt et al., 201610. These data 
makes use of Hi-C data described in Dixon et al., 201511. TAD boundaries were identified 
using the insulation score approach proposed by Crane et al., 201512 at 40kb resolution. 
 
To further explore target gene prioritisation, we used DEPICT13  
(https://data.broadinstitute.org/mpg/depict/); an  integrative tool, which based on 
predicted gene function, prioritizes the most likely target genes of risk SNPs uses gene 
expression data from multiple sources. SNP associations were pruned to a set of 
independent signals by r2>0.05 in YRI, CEU and CHB populations additionally retaining SNPs 
for which LD metrics could not be obtained. We considered all target genes with a FDR 
Q<0.05 as well as the top gene per SNP. 
 
Finally, as an adjunct to our GWAS-based analysis, we also considered the classical cancer 
susceptibility genes (CSGs) whose mutation in the germline is responsible for the various 
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Mendelian forms of cancer. These were obtained from the COSMIC Cancer Gene Census14 
(https://cancer.sanger.ac.uk/census; accessed February 2018). 
 
Genetic association enrichment for approved drugs  
Data on the status of drug-target combinations along the various stages of drug 
development from pre-clinical through to regulatory approval were obtained by 
interrogation of the Informa Pharmaprojects database 
(https://pharmaintelligence.informa.com/; accessed January 2018). In addition to drugs 
assessed by Pharmaprojects, cancer drugs approved for use in cancer susceptibility gene 
carriers were also considered. Drugs with a specific indication for symptom control only, 
were excluded. Records were retained if target genes could be unambiguously mapped to 
HUGO Gene Nomenclature Committee at the European Bioinformatics Institute (HGNC; 
https://www.genenames.org) identifiers. We assessed whether drug targets with 
supporting genetic evidence were more likely to be approved in the drug development 
pipeline, by constructing a two by two table of genes and counts corresponding to whether 
a gene product has genetic support as a drug target at respective stages of development 
(e.g. comparing approved drugs with those only reaching preclinical stages). Test of 
association was Fisher’s exact test, with the Wald test used to quantity effect size and 95% 
confidence intervals. A P-value of 0.05 (two-sided) was considered as statistically significant. 
All statistical calculations were performed using R version 3.2 software. 
 
Druggability annotation of target genes 
Targets of FDA-approved drugs were obtained from Santos et al., 201715. Genes were 
filtered for  protein-coding genes and canSAR v4 Cancer Protein Annotation Tool (CPAT)16 
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used to identify proteins with >95% sequence homology to existing drug targets. CPAT was 
also used to extract structure- and ligand-based druggability assessments from canSAR 
(https://cansar.icr.ac.uk/; accessed 2018). Network-based druggability scores for proteins 
were  based on Mitsopoulos et al., 201517. 
 
Finally, we assessed all 355,305 active compounds identified by canSAR against their targets 
using Probe Miner18, which catalogues >1.8 million compounds for their suitability as 










Linking risk SNPs to target genes 
Across 37 cancers we identified 955 risk loci. To link sentinel risk SNPs to respective target 
gene(s), we first considered genes within regions of LD to which risk SNPs mapped, imposing 
a range of r2 thresholds. After which, we considered all genes localising within the risk SNP-
defined TAD boundaries. Finally, we based linkage on the  gene prioritisation approach 
implemented in DEPICT13. These three approaches yielded between 394 and 7,379 protein-
coding target genes (Fig. 1, Supplementary Tables 1-3).  
 
Genetic association enrichment for approved drugs  
By interrogating the Informa Pharmaprojects database, we identified 1,706 unique genes 
that were the target of 3,435 unique therapeutic agents for cancer (Supplementary Table 
4). These were grouped according to the furthest point reached across five stages of drug 
development pipeline: (1) Pre-clinical (i.e. in vitro and in vivo dosing and toxicity 
assessment), (2) Phase I (safety and dosage), (3) Phase II (efficacy and side effects), (4) Phase 
III and pre-registration (efficacy and monitoring of adverse reactions), (5) Approved.  
 
We first considered all targets from the Pre-clinical stage and assessed the level of 
enrichment for being successfully approved conferred by genetic information. All of the 
methods linking SNPs to target genes provided evidence for enrichment. For the LD-based 
assessment enrichment was strongly correlated with r2 values; imposing a r2 value >0.9 
resulted in 2.00-fold improvement in targeting of Pre-clinical drugs (95% CI: 1.14-3.48, 
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P=0.02, Fig. 2A, Table 1). The comparative enrichment associated with COSMIC catalogued 
CSGs was 6.61-fold (95% CI: 3.17-13.78, P = 2.23 x 10-6, Fig. 2A, Table 1).   
 
We reasoned that a target’s failure to progress along the Pre-clinical and Phase I stages is 
often for reasons unrelated to efficacy, and therefore next considered all targets from Phase 
II and above, and assessed the degree of enrichment for approval conferred by genetic 
information. As with the analysis of pre-clinical targets incorporating genetic association 
information led to enrichment for approval (Fig. 2B, Table 2). The strongest enrichment 
from the LD-based approach was attained after imposing an r2 value >0.9 which was 
associated with a significant 2.75-fold difference (95% CI: 1.42-5.35, P = 4.2 x 10-3, Fig. 2B). 
The comparative enrichment associated with COSMIC catalogued CSGs was 5.72-fold (95% 
CI: 2.35-13.89, P = 8.41 x 10-5).   
 
Potential for re-purposing non cancer drugs 
To explore the application of genetics to inform drug re-purposing we first identified 
approved drugs used in the treatment of non-oncological disease. We then examined 
discordant pairing of drug indications and cancer associations. We identified 15 genes for 
which an approved drug is currently available with genetic support (Table 3). Notable 
examples included: (1) TGFB1 at 19q13.2, where a targeted drug is used in the treatment of 
rheumatoid arthritis and is the site of an association with colorectal cancer risk19; (2) VDR at 
12q13.11, which is targeted by drugs treating osteoporosis and is a risk locus for prostate 
cancer20;  (3) At 11q14.3 TYR is the target of an approved drug used in the treatment of skin 
disorders, which is also the site of a risk locus for melanoma21, squamous cell carcinoma22 
and basal cell carcinoma23; (4) PTGIR at 19q13.32 which is targeted by a drug used in the 
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treatment of transplant rejection and peripheral vascular disease, and is the site of a chronic 
lymphocytic leukaemia risk locus24.  
 
Availability of cancer germline genetic information 
Supporting cancer germline genetic information for prospective targets is available from 
https://cansar.icr.ac.uk/ (Figure 3). For each uniprot identifier, a report has been generated 
detailing whether the given gene has been annotated as containing cancer-causing germline 
mutations by the COSMIC germline cancer gene census14, as well as whether any variants 











Our findings support the potential of human genetics to guide the identification of drug 
targets, addressing a productivity-limiting step in drug development and a bottleneck to 
realising the vision of precision oncology. Specifically, we have demonstrated that 
knowledge of cancer susceptibility genes identified by GWAS can be used to maximise 
discovery of likely Pre-clinical and Phase II targets, thereby empowering drug development 
programs. Our analysis benefits from the larger of risk loci for cancer that have been 
identified over recent years thereby providing greater power than earlier studies1.  
 
Significant enrichment of pre-clinical and phase II targets was also shown by incorporating 
information on the classical CSGs. Given that many of the CSGs are somatically mutated 
these targets may have already directly influenced recent drug development programs. 
Indeed, we observed a highly significant enrichment for CSGs being selected for pre-clinical 
validation per se (OR=11.37; CI=7.44-17.37; P=5.19 × 10-20), which is greater than that 
afforded to genes simply implicated by GWAS (r2>0.9 targets (OR=1.44; CI=1.14-1.81; 
P=0.003).  
 
We employed a number of methods to map target genes to cancer risk SNPs, incorporating 
LD blocks, TAD regions and gene expression. We found that genes implicated by LD r2>0.9 
method showed the greatest enrichment for drug approval. While compatible with the 
functional basis of many GWAS associations being due to the most proximal gene(s), this 
does not preclude the possibility of longer-range tissue-specific mechanisms that are less 
amenable to detection by our approach. Therefore future endeavours of this kind will likely 
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benefit from more detailed experimental investigation of the biological mechanism 
underpinning cancer risk loci. While the TAD-based strategy is likely to be always beset by 
the issue of capturing too many genes, strategies based on integration of GWAS and multi-
omics as per DEPICT13 are likely to improve making them attractive sources of genetic 
information. To investigate regulatory interactions across all cancer risk loci we made use of 
publicly available Hi-C data from human embryonic stem-cells, noting the observation of 
Dixon et al., 201225 that TAD boundaries are relatively stable across cell types. However, the 
increasing availability of tissue- and cancer-specific Hi-C data is likely to improve efforts to 
identify target genes of specific cancer risk regions. 
 
In concert with our primary analysis we identified a number of possible opportunities for 
drug re-purposing, informed by cancer germline genetics. These extend the potential of pre-
existing therapies and highlight that pathways subverted by cancers may also be altered in 
other diseases.  
 
For pragmatic purposes we considered all cancers assuming generic effects exist at least 
across some cancers in order to maximise study power. We do however acknowledge that 
this is in essence crude since certain cancer subtypes can show specific associations with risk 
SNPs, reflective of differences in their biology. For example, ER-positive and negative breast 
cancers26,27 as well as combinations of 1p/19q co-deletion, TERT promoter and IDH mutation 
in glioma28,29. The future availability of larger datasets which will afford the identification of 
additional risk SNPs will open up the possibility of fine-tuned analyses. In addition we make 
the assumption that cancer risk variants act directly to influence cancer initiation or 
progression. However, this does not preclude the existence of a limited subset which may 
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have indirect mechanisms, such as at 15q25.1 where the association with lung cancer is 
likely due to smoking30. 
 
One caveat to using all forms of germline genetics as a mechanism for prioritisation of drug 
development is the assumption that susceptibility per se is also reflective of progression, 
which may not always be the case. As with other studies, we have used drug approval as a 
surrogate for drug efficacy. This assumption will only however serve to make our estimates 
conservative. We additionally acknowledge our lack of inclusion of generic drugs, however 
as the vast majority of these have a broad range of targets we do not regard this as 
significantly impacting our findings. Considering the extent to which cancer genes 
implicated by GWAS that are not currently in the drug development pipeline might 
represent good candidates we performed multi-faceted druggability analyses incorporating 
assessments of the 3D structures of the target protein and any associated protein 
complexes, chemical properties of known ligands of the target, and the target’s position and 
role within the human interactome. Ranking target-indication pairings by criteria including 
novelty relative to existing targets and predicted attrition risk (Supplementary Tables 5 and 
6). Of 1,292 genes annotated to GWAS SNPs by r2>0.9; 977, 486 and 1,287 had druggability 
assessments by network, structure and ligand-based prediction respectively. Of note is the 
observation that 29 of these can be targeted by existing high-quality probes and thus 
represent good candidates for being prioritised in for future studies. 
 
In conclusion, we have demonstrated enrichment for targets implicated by cancer risk 
variants being more successful in the drug development pipeline, providing a rationale for 
germline genetics empowering cancer drug discovery. Mapping approved drug targets back 
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to cancer GWAS signals enables identification of both novel drug targets and patient 
populations. To benefit the wider community the cancer germline information used in this 
study is available at https://cansar.icr.ac.uk. Collectively our findings show the value of 
incorporating information from germline cancer genetics as part of interdisciplinary, data-
driven approaches to inform drug discovery in oncology. 
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FIGURE AND SUPPLEMENTARY TABLE LEGENDS 
 
Figure 1: Summary of analytical strategy.  
 
Figure 2: Enrichment of approved cancer drug targets incorporating genetic evidence 
relative to pre-clinical (A) and phase II (B) targets.  TAD, topologically associating domain; 
N, number; DEPICT, Data-driven expressed prioritised integration for complex traits. Data 
based on Tables 1-2. 
 
Figure 3: Integration of cancer germline genetics information into canSAR. Available 
germline genetic evidence can be searched for by target on cansar.icr.ac.uk or directly at 
https://cansar.icr.ac.uk/cansar/molecular-targets/P23458/germline_genetics/ where 
P23458 is the uniprot identifier for the target of interest.  
 
Supplementary Table 1: Cancer risk SNPs. 
 
Supplementary Table 2: Mapping cancer risk SNPs to gene transcripts by LD- and TAD-
based approaches. 
 
Supplementary Table 3: DEPICT gene prioritization of cancer risk SNPs 
 
Supplementary Table 4: Number of unique genes targeted by cancer therapies at the last 
recorded stage of development.  
 
Supplementary Table 5: Summary of canSAR druggability assessments of target genes 
implicated by cancer germline genetics. Druggability assessments were obtained from 
canSAR (https://cansar.icr.ac.uk/) and high-quality probe annotations obtained from 
ProbeMiner (http://probeminer.icr.ac.uk/). 
 
Supplementary Table 6: CanSAR druggability assessments for target genes implicated by 
cancer germline genetics.
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 Pre-clinical drug Enrichment (pre-clinical vs approved) 
Method Approved with 
genetic support (N) 
Not approved with 
genetic support (N) 
Approved with no 
genetic support (N) 
Not approved with no 
genetic support (N) 
P-value OR (95% CI) 
TAD 49 264 66 457 0.22 1.28 (0.86-1.92) 
r
2
 > 0.1 36 186 79 535 0.21 1.31 (0.85-2.01) 
r
2
 > 0.2 28 141 87 580 0.26 1.32 (0.83-2.11) 
r
2
 > 0.3 26 125 89 596 0.19 1.39 (0.86-2.25) 
r
2
 > 0.4 24 109 91 612 0.13 1.48 (0.90-2.42) 
r
2
 > 0.5 22 92 93 629 0.08 1.62 (0.97-2.70) 
r
2
 > 0.6 21 89 94 632 0.10 1.59 (0.94-2.67) 
r
2
 > 0.7 19 77 96 644 0.08 1.65 (0.96-2.86) 
r
2
 > 0.8 19 69 96 652 0.03 1.87 (1.08-3.25) 
r
2
 > 0.9 19 65 96 656 0.02 2.00 (1.14-3.48) 
COSMIC Germline 15 16 100 705 2.23 × 10
-6
 6.61 (3.17-13.78) 
DEPICT 8 33 107 688 0.25 1.56 (0.70-3.46) 
 
Table 1: Enrichment of approved cancer drug targets supported by genetic evidence relative to pre-clinical targets. OR, odds ratio; CI, 
confidence interval; TAD, topologically associating domain; N, number; DEPICT, Data-driven expressed prioritised integration for complex 
traits. Enrichment was calculated by constructing a two by two table of genes and counts corresponding to whether a gene product has 
genetic support at the respective stages of drug development (i.e. approved compared with pre-clinical). Test of association was Fisher’s exact 
test, with the Wald test used to quantity effect size and 95% confidence intervals. A P-value of 0.05 (two-sided) was considered as statistically 
significant.
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 Phase II drug Enrichment (phase II vs approved) 
Method Approved with 
genetic support (N) 
Not approved with 
genetic support (N) 
Approved with no 
genetic support (N) 
Not approved with no 
genetic support (N) 
P-value OR (95% CI) 
TAD 49 100 66 213 0.04 1.58 (1.02-2.45) 
r
2
 > 0.1 36 72 79 241 0.10 1.53 (0.95-2.45) 
r
2
 > 0.2 28 50 87 263 0.07 1.69 (1.00-2.85) 
r
2
 > 0.3 24 46 89 267 0.06 1.70 (0.99-2.90) 
r
2
 > 0.4 22 40 91 273 0.05 1.80 (1.03-3.15) 
r
2
 > 0.5 21 32 93 281 0.02 2.08 (1.15-3.75) 
r
2
 > 0.6 19 30 94 283 0.02 2.11 (1.15-3.86) 
r
2
 > 0.7 19 26 96 287 0.02 2.18 (1.16-4.12) 
r
2
 > 0.8 19 23 96 290 9.2 × 10
-3
 2.50 (1.30-4.78) 
r
2
 > 0.9 19 21 96 292 4.2 × 10
-3
 2.75 (1.42-5.35) 
COSMIC Germline 15 8 100 305 8.41 × 10
-5 
5.72 (2.35-13.89) 
DEPICT 8 9 107 304 0.09 2.52 (0.95-6.71) 
 
Table 2: Enrichment of approved cancer drug targets supported by genetic evidence relative to phase II targets. OR, odds ratio; CI, 
confidence interval; TAD, topologically associating domain; N, number; DEPICT, Data-driven expressed prioritised integration for complex 
traits. Enrichment was calculated by constructing a two by two table of genes and counts corresponding to whether a gene product has 
genetic support at the respective stages of drug development (i.e. approved compared with phase II). Test of association was Fisher’s exact 
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Gene Entrez Additional genes targeted by drug Disease/s Locus Cancer type 
ALOX5 240  Asthma, Chronic obstructive pulmonary disease 10q11.21 Prostate Cancer 
CFTR 1080  
Cystic fibrosis, Diarrhoea, short-bowel 
syndrome, Irritable bowel syndrome, 
diarrhoea-predominant infection, GI tract 
infection, HSV infection, HIV/AIDS 7q31.2 
Barrett's esophagus/esophageal 
adenocarcinoma 
CLCN2 1181  
Chronic constipation, Irritable bowel syndrome, 
GI motility dysfunction,  3q27.1 Esophageal adenocarcinoma 
CRHR1 1394 CRHR2 (1395) Anxiety, unspecified insomnia 17q21.31 Ovarian cancer in BRCA1 carriers 
DDC 1644  Parkinson's disease 7p12.1 Childhood ALL 
GABBR1 2550  
Spasticity, Multiple sclerosis, Alcohol addiction, 
Cerebral palsy, Spinal cord injury, Dystonia 6p22.1 
Barrett's esophagus/esophageal 
adenocarcinoma 
GBA 2629  Gaucher's disease 1q22 Gastric adenocarcinoma 
INSR 3643  Diabetes Type 1, Diabetes Type 2 19p13.2 
Renal Cell Carcinoma/Differentiated 
Thyroid Cancer 
PDE4D 5144 
PDE4A (5141)/PDE4B (5142)/PDE4C 
(5143) 
COPD, Asthma, Non-alcoholic steatohepatitis, 
Eczma, Alzheimer's disease, Schizophrenia, 
Rhinitis, Psoriasis 5q12.1 Esophageal cancer/Breast cancer 
PLG 5340  
Venous thrombosis, Myocardial infarction, 
Pulmonary thrombosis 6q26 Prostate Cancer 
PTGIR 5739  
Pulmonary hypertension, Transplant rejection, 
Peripheral vascular disease, Limb ischaemia 19q13.32 CLL 
SLC6A3 6531  Depression, CNS diagnosis, ADHD 5p15.33 Pancreatic cancer 
TGFB1 7040  
Wound healing, conjunctivitis, Asthma, Eczema, 
Rhinitis, Rheumatoid arthritis, Hyperuricaemia, 
Multiple Sclerosis, Restenosis 19q13.2 Colorectal cancer 
TYR 7299  Skin disorder 11q14.3 
Melanoma/Squamous cell 
carcinoma/Basal cell carcinoma 
VDR 7421  
Osteoperosis, Keratosis, Secondary 
hyperparathyroidism, Psoriasis, 
Osteodystrophy, Hypophosphataemia, 
Palmoplantar pustulosis, Ichthyosis 12q13.11 Prostate Cancer 
 
Table 3: Opportunities for drug re-purposing informed by germline cancer genetics. Targets annotated to cancer risk SNPs by r2>0.8 were 
assessed for overlap with approved non-oncology drugs.
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